Quantcast
Home > Quotes > AVXL

Anavex Life Sciences Corp. Common Stock (AVXL) Quote & Summary Data

AVXL 
$3.26
*  
0.01
0.31%
Get AVXL Alerts
*Delayed - data as of Jun. 20, 2019 12:08 ET  -  Find a broker to begin trading AVXL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AVXL Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 3.24 / $ 3.27
1 Year Target
10
Today's High / Low
$ 3.34 / $ 3.22
Share Volume
145,910
50 Day Avg. Daily Volume
380,789
Previous Close
$ 3.25
52 Week High / Low
$ 4.35 / $ 1.25
Market Cap
165,389,531
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.57

Intraday Chart

Shares Traded

Share Volume:
145,910
50 Day Avg. Daily Volume:
380,789

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.52

Trading Range

The current last sale of $3.26 is 160.80% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.34 $ 4.35
 Low: $ 3.22 $ 1.25

Company Description (as filed with the SEC)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ("CNS") diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Our lead compound, ANAVEX┬«2-73, is being developed to treat Alzheimer's disease, Parkinson's disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 ("MECP2"). Our total portfolio currently consists of five programs.  ... More ...  



Risk Grade

Where does AVXL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.29
Open Date:
Jun. 20, 2019
Close Price:
$ 3.25
Close Date:
Jun. 19, 2019


Consensus Recommendation

Analyst Info